home.aspx
 
EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...

Almirall

SHARESHARESHARE
Almirall is a global company based in Barcelona dedicated to providing valuable medicines and medical devices through its R&D, agreements and alliances. Our work covers the whole of the drug value chain. A consolidated growth allows us to devote our talent and efforts towards speciality areas and particularly to further grow as a leading Dermatology player. We are a specialist company, enabling us to accomplish the purpose of taking our innovative products wherever they are needed.
SHARESHARESHARE

RELATED NEWS


Spain’s Almirall has taken an option granting rights to develop and market Dermira’s eczema drug lebrikizumab in Europe, in a bid to take on Sanofi/Regeneron’s recently approved Dupixent. The companies had struck an option and license agreement in February which granted Almirall European rights to the drug in atopic dermatitis, also known as eczema, and certain other indications.
Barcelona-based Almirall paid $30 million up front to Dermira and will pay a further $50 mil...


READ MORE

One by one, drugmakers have been handing over millions of dollars to the U.S. government to settle kickback allegations. And Almirall is the latest.The Spain-based drugmaker agreed to pay $3.5 million to the Department of Justice (DOJ) and $3.1 million to the California Department of Insurance to wrap up claims that it paid doctors to prescribe more of its skin drugs. Based on allegations outlined in a whistleblower lawsuit, the government said that Almirall's Aqua Pharmaceuticals business w...

READ MORE

Almirall has signed a new research collaboration with Chinese biotech HitGen, to find potential new oral therapies for moderate to severe atopic dermatitis – otherwise known as eczema. The Spanish dermatology specialist is conducting a multi-target research collaboration with companies using technology involving DNA-encoded libraries, for targets in atopic dermatitis to develop novel oral chemical entities for patients suffering from moderate to severe atopic dermatitis. DNA-encoded librar...

READ MORE

NICE has recommended in draft guidance that UCB’s Cimzia can receive regular NHS funding for plaque psoriasis, but decided that Almirall’s rival Ilumetri does not represent good value for money. Cimzia (certolizumab pegol) was approved in Europe in the new indication of plaque psoriasis earlier this year, adding to a list of uses including rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. While there are a number of other anti-TNF drugs approved in psoriasis, in...

READ MORE

EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...